Information Provided By: 
Fly News Breaks for December 23, 2016
NEO
Dec 23, 2016 | 07:19 EDT
After NeoGenomics slightly lowered its 2016 guidance, Cantor analyst Bryan Brokmeier says that his 2017 outlook for the company has not changed. Moreover, he says that the company's new credit facility and redeemed preferred shares leave it "better positioned for strategic acquisitions" of oncology diagnostic labs. The analyst believes that the stock's valuation is "compelling," and he keeps an $11 price target and an Overweight rating on the shares.
News For NEO From the Last 2 Days
There are no results for your query NEO
